Back to NewsletterNewsletter

    This Week at Peak Human: The Lp(a) Drug Worked — and Prevented Nothing

    Pelacarsen cut Lp(a) by 78% and prevented zero cardiovascular events — plus the first randomized frailty win for stem cells, the strongest peptide evidence yet, and an early Alzheimer's signal from lithium.

    Nov 14, 20265 min read

    A note from Dr. Goel

    This week brought the results everyone in the Lp(a) world had been waiting for — and they weren't what the biomarker promised. I've also refreshed three evidence pages this week: Stem Cell Therapy got its first randomized frailty-trial data, Peptide Therapy got a new tesamorelin meta-analysis, and Lithium Orotate got an early Alzheimer's signal worth knowing about. Here's what's new at Peak Human this week, and what I'd actually act on.

    — Dr. Sanjeev Goel

    🔬 This week's deep dive: The Lp(a)HORIZON Results Are In

    Lipoprotein(a), or Lp(a), is the cardiovascular risk factor diet and exercise can't touch — it's almost entirely genetic. Pelacarsen was built specifically to lower it, on the theory that if elevated Lp(a) causes heart attacks and strokes, lowering it should prevent them. This month, the Lp(a)HORIZON outcomes trial reported whether that theory holds. It lowered Lp(a) by about 78%. It prevented nothing.

    Lp(a)HORIZON randomized 8,350 patients with established cardiovascular disease and elevated Lp(a) to pelacarsen or placebo and followed them for a median of 4.7 years. Events occurred in 12.3% of the pelacarsen group vs. 12.1% on placebo — hazard ratio 1.02 (95% CI 0.90–1.15). Even patients with baseline Lp(a) ≥90 mg/dL showed a hazard ratio of 1.00 (95% CI 0.87–1.15). The mechanism worked (Lp(a) fell 78%); the hypothesis that lowering it this way prevents events did not hold up. Other Lp(a)-lowering drugs (olpasiran, muvalaplin) are still in their own outcome trials — this isn't the end of the Lp(a) story.

    🧬 Site update: Stem Cell Therapy's First Frailty Trial

    I refreshed our Stem Cell Therapy evidence page this week. A randomized, placebo-controlled Phase 2b trial of laromestrocel — an investigational bone-marrow-derived stem cell product — improved 6-minute walk distance by 63.4 meters vs. placebo at 9 months in 148 older adults with frailty (95% CI 17.1–109.6, p=0.008). It's the first placebo-controlled evidence that a cell therapy can move a physical-function outcome in aging frailty — one investigational, not-yet-FDA-approved product, not the unregulated stem cell treatments sold at many wellness clinics.

    💉 Site update: The Best-Evidenced Peptide Just Got Better Data

    Our Peptide Therapy page now reflects a new 2026 meta-analysis of five randomized trials of tesamorelin — the one therapeutic peptide with FDA approval and real trial data behind it. Pooled vs. placebo: visceral fat down ~28 cm², liver fat down ~4 percentage points, lean body mass up 1.4 kg, with no disruption to glucose control. That evidence is specific to tesamorelin's approved indication (HIV-associated lipodystrophy) — popular compounded peptides like BPC-157 still rest mostly on animal data.

    🧠 Site update: An Early Alzheimer's Signal for Lithium

    Our Lithium Orotate entry was updated with two 2025–2026 findings worth knowing even if you never take it. A Harvard Nature study found brain lithium depletion is one of the earliest molecular changes in Alzheimer's, and lithium orotate specifically reversed the pathology in mice. Separately, a small human pilot trial of a different salt (lithium carbonate) nearly halved verbal-memory decline over two years in adults with mild cognitive impairment, though it missed its own strict pre-specified statistical threshold. Early and hypothesis-generating — not proof.

    My take: A negative trial with a clean mechanism is more useful than a positive trial with a messy one — and this is about as clean a test of the "lowering Lp(a) prevents events" hypothesis as we're likely to get. It came back null. If your Lp(a) is high, don't wait on a drug that isn't approved for this. In the FOURIER trial, lowering LDL cholesterol helped the high-Lp(a) subgroup the most — 40 people needed treatment to prevent one event, vs. 105 in the low-Lp(a) group. That lever already works today.

    If you don't already know your Lp(a) number, it's worth checking once — it's measured essentially once in a lifetime, since it's almost entirely genetically determined.

    📰 Longevity news worth your minute

    The Lp(a) story isn't over. Amgen's olpasiran and Lilly's muvalaplin — two other Lp(a)-lowering drugs with different mechanisms — are still running their own outcome trials; Lp(a)HORIZON's investigators were explicit that this result doesn't settle the Lp(a) hypothesis.

    The FDA kept issuing warning letters in 2026 against unapproved stem cell and exosome products marketed for anti-aging, citing serious adverse events — a reminder that investigational trial data (like this week's frailty result) is not the same thing as what's sold at a walk-in clinic.

    Important disclaimer

    This newsletter is for educational purposes only and is not medical advice. Compounds discussed may be investigational and not FDA-approved. Nothing here is a recommendation to start, stop, or change any treatment. Peptide and metabolic therapies carry real risks and should only be used under qualified medical supervision. Always consult your physician before making health decisions.

    Written by

    Dr. Sanjeev Goel, MD

    Longevity physician with 20+ years of experience in preventative and precision medicine.

    Subscribe
    VIP Community

    Unlock Your Full Potential